CompletedNot applicableNCT01624220

A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy

The goal of the first part of this clinical research study is to learn how to deliver more accurate radiation treatment of tumors in the spine. Researchers also want to learn how internal organs might move during radiation treatment. The goal of the second part of this study is to learn if it is safe to allow slightly more radiation to the normal esophagus when spinal tumors close by are being treated. This may result in better tumor control.

Checked against the public recordLast updated May 12, 2026 · Source: ClinicalTrials.gov

StatusCompleted
PhaseNot applicable
U.S. locations1
SponsorM.D. Anderson Cancer Center
01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Not applicable
Sponsor
M.D. Anderson Cancer Center
Interventions being studied
Radiation: Spinal SBRT (Standard Dose); Radiation: Spinal SBRT (Higher Dose); Procedure: Gold Seed Implantation; Behavioral: Questionnaires
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: 1. STAGE 1: \>/= 18 years old 2. STAGE 1: Pathologically confirmed diagnosis of cancer, including, but not limited to non-small cell lung cancer, breast, prostate, renal cell, melanoma, gastrointestinal, sarcoma, thyroid, head and neck primary, and carcinoma of unknown primary 3. STAGE 1: Signed informed consent 4. STAGE 2: 1-3 above, and Patients undergoing single fraction spinal SBRT Exclusion Criteria: 1. STAGE 1: Patient with radiosensitive histologies (lymphoma, multiple myeloma, small cell carcinomas, germ cell tumors) 2. STAGE 1: Extensive (\> 50%) height loss of the involved vertebral body 3. STAGE 1: Inability to tolerate lying flat on treatment table for greater than 30 minutes 4. STAGE 1: Pregnancy 5. STAGE 2: Prior irradiation of the spine site and level to be treated 6. STAGE 2: Patients with primary disease arising in the posterior elements of the VB in question 7. STAGE 2: History of Barrett's esophagus, esophageal webbing, stricture, or fistula 8. STAGE 2: Prior radiation to the esophagus

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of Texas MD Anderson Cancer CenterHouston, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 12, 2026. Always confirm current availability with the study team.

View original record ↗